Log in to your Inderes Free account to see all free content on this page.

Calliditas Therapeutics

Less than 1K followers

All

Webcasts

Press releases

ShowingAll content types

Regulatory press release9/30/2024, 12:30 PM

Bulletin from the extraordinary general meeting of Calliditas Therapeutics AB (publ)

Calliditas Therapeutics

Regulatory press release9/16/2024, 1:30 PM

Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm

Calliditas Therapeutics

Regulatory press release9/3/2024, 10:15 AM

Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei

Calliditas Therapeutics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release9/3/2024, 10:00 AM

Notice of extraordinary meeting of Calliditas Therapeutics AB (publ)

Calliditas Therapeutics

Press release8/15/2024, 9:45 AM

Redeye: Calliditas Update - The Final Countdown

Calliditas Therapeutics

Calliditas Therapeutics, Audiocast with teleconference, Q2'24

Webcast8/13/2024, 12:30 PM

Calliditas Therapeutics, Audiocast with teleconference, Q2'24

Calliditas Therapeutics

Regulatory press release8/13/2024, 5:00 AM

Calliditas Therapeutics: Calliditas Interim Report January to June 2024

Calliditas Therapeutics

Press release8/5/2024, 5:00 AM

Calliditas Therapeutics: Invitation to the presentation of Calliditas's interim report January - June 2024

Calliditas Therapeutics

Regulatory press release7/31/2024, 12:00 PM

Number of shares and votes in Calliditas Therapeutics

Calliditas Therapeutics

Press release7/26/2024, 3:00 PM

Calliditas Therapeutics: Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy

Calliditas Therapeutics

Regulatory press release7/26/2024, 6:00 AM

Calliditas Therapeutics: Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis

Calliditas Therapeutics

Press release7/4/2024, 6:30 AM

Calliditas Therapeutics: Launch of Phase 3 clinical trial with Nefecon in Japan

Calliditas Therapeutics

Press release6/18/2024, 10:15 AM

Calliditas Therapeutics: Calliditas provides setanaxib patent update

Calliditas Therapeutics

Regulatory press release6/17/2024, 3:30 PM

Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)

Calliditas Therapeutics

Regulatory press release5/30/2024, 6:00 PM

Calliditas Therapeutics: Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo[®] for the treatment of IgA nephropathy

Calliditas Therapeutics

Calliditas Therapeutics R&D Day, 2024

Webcast5/30/2024, 1:00 PM

Calliditas Therapeutics R&D Day, 2024

Calliditas Therapeutics

Press release5/28/2024, 12:00 PM

Calliditas Therapeutics Presents Data at the 61[st] European Renal Association Congress

Calliditas Therapeutics

Regulatory press release5/28/2024, 6:30 AM

Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei Corporation

Calliditas Therapeutics

Press release5/24/2024, 5:11 AM

Redeye: Calliditas Q1 - Powerful launch momentum

Calliditas Therapeutics

Calliditas Therapeutics, Audiocast with teleconference, Q1'24

Webcast5/23/2024, 12:30 PM

Calliditas Therapeutics, Audiocast with teleconference, Q1'24

Calliditas Therapeutics

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.